A device developed by Cleveland Clinic doctors to help eliminate blood clot formation in a small part of the heart is now available for widespread clinical application. Approval for the AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion system by the Food and Drug Administration was granted earlier this year and its commercial availability was launched this fall. Developed by Delos Cosgrove, MD, President and CEO of Cleveland Clinic, and A. Marc Gillinov, MD, Surgical Director of the Center for Atrial Fibrillation, the AtriClip is designed to eliminate blood flow from the left atrium to the left atrial appendage (LAA), a small sac-like structure attached to the atrium.
To continue reading this article or issue you must be a paid subscriber.
Sign in
